Original Article
DOI: https://doi.org/10.70749/ijbr.v3i12.2699

INDUS JOURNAL OF BIOSCIENCE RESEARCH
https://ijbr.com.pk
ISSN: 2960-2793/ 2960-2807

Clinical Applications of Nanotechnology in Drug Delivery for Surgical Patients: Advances in Targeting and Controlled Release

Muhammad Numair Kashif[1], Aziz ur Rahman[2], Iqra Ramzan[3], Madiha Muzammil[4], Awais Ahmed Uttra[5], Rida Kainat[6]

[1]Bahauddin Zakariya University, Multan, Pakistan
[2]Department of Pharmacy, University of Malakand, Khyber Pakhtunkhwa, Pakistan
[3]Department of Biotechnology, University of Okara, Okara, Pakistan
[4]CABB, University of Agriculture Faisalabad, Pakistan
[5]Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Thailand
[6]Department of Biochemistry, Fazaia Ruth Pfau Medical College, Paksitan

ARTICLE INFO

Keywords: Drug Delivery Systems, Nanotechnology, Surgical Patients, Targeted Drug Delivery, Controlled Drug Release, Therapeutic Efficacy, Adverse Effects, Precision Medicine

Correspondence to: Awais Ahmed Uttra, Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Thailand.
Email: awaisutra@yahoo.com

Declaration
Authors' Contribution: All authors equally contributed to the study and approved the final manuscript.

Conflict of Interest: No conflict of interest.

Funding: No funding received by the authors.

Article History
Received: 01-10-2025 Revised: 13-12-2025
Accepted: 24-12-2025 Published: 30-12-2025

ABSTRACT

This quantitative study examined the clinical applications of nanotechnology-based drug delivery systems in surgical patients, with emphasis on advances in targeted delivery and controlled drug release. A prospective comparative research design was employed in the surgical and perioperative units of a tertiary care hospital, involving a total sample of 120 adult surgical patients selected through consecutive sampling. Participants were divided into two equal groups receiving either nanotechnology-based drug delivery systems or conventional drug formulations. Quantitative data were collected on targeted drug delivery effectiveness, therapeutic outcomes, and adverse effect occurrence. Statistical analyses, including chi-square tests and independent samples t tests, were used to evaluate associations and group differences. The findings revealed that nanotechnology-based drug delivery systems achieved significantly higher rates of effective drug targeting and were associated with reduced adverse drug effects compared to conventional methods ($p < .01$). Controlled drug release through nanotechnology demonstrated improved therapeutic performance and enhanced drug safety in the postoperative period. These results support the clinical effectiveness of nanotechnology-enabled drug delivery in surgical care and highlight its potential role in advancing precision pharmacotherapy and improving patient outcomes.

INTRODUCTION

Overview of Nanotechnology in Modern Medicine

Nanotechnology refers to the manipulation and application of materials at the nanoscale, typically between 1 and 100 nanometers, where unique physical, chemical, and biological properties emerge. In modern medicine, nanotechnology has gained significant attention due to its potential to overcome limitations associated with conventional diagnostic and therapeutic approaches. At this scale, nanoparticles can interact with biological systems at the molecular level, enabling enhanced drug solubility, improved bioavailability, and precise interactions with cellular targets. These advantages have positioned nanotechnology as a transformative innovation across multiple medical disciplines, including oncology, cardiology, infectious diseases, and surgery [1].

In clinical practice, traditional drug delivery methods often face challenges such as poor tissue specificity, rapid drug degradation, systemic toxicity, and suboptimal therapeutic concentrations at the target site. These limitations are particularly problematic in surgical patients, who often require precise perioperative drug management to reduce complications, control pain, prevent infection, and promote healing. Nanotechnology-based drug delivery systems offer innovative solutions by enabling drugs to be encapsulated, protected, and delivered in a controlled and targeted manner, thereby enhancing therapeutic efficacy while minimizing adverse effects [2].

The integration of nanotechnology into clinical medicine reflects a broader shift toward precision-based and patient-centered care. As surgical procedures become increasingly complex and minimally invasive, there is a

growing demand for advanced drug delivery systems that can adapt to the dynamic physiological conditions of surgical patients. Nanotechnology addresses this demand by providing platforms capable of responding to specific biological triggers, such as pH, temperature, or enzymatic activity, making it highly relevant to modern surgical practice [3].

Drug Delivery Challenges in Surgical Patients

Surgical patients present unique pharmacological challenges due to physiological stress responses, altered tissue perfusion, inflammation, and changes in drug metabolism during the perioperative period. Conventional systemic drug administration often results in uneven drug distribution, exposing non-target tissues to high drug concentrations while failing to achieve optimal levels at the surgical site [4]. This can lead to complications such as systemic toxicity, delayed wound healing, inadequate pain control, and increased risk of postoperative infections [5].

Another critical challenge in surgical drug delivery is maintaining sustained therapeutic drug levels over time. Many drugs administered during and after surgery require frequent dosing to maintain efficacy, increasing the risk of noncompliance and adverse effects. For example, antibiotics may need repeated administration to prevent surgical site infections, while analgesics may cause systemic side effects such as respiratory depression or gastrointestinal complications. These issues highlight the need for drug delivery systems that can provide controlled and prolonged drug release at the site of action [6].

Additionally, certain surgical conditions—such as tumors, ischemic tissues, or inflamed surgical wounds—possess complex microenvironments that limit effective drug penetration. Barriers such as abnormal vasculature, elevated interstitial pressure, and biological membranes can hinder drug delivery. Nanotechnology-based systems are designed to overcome these barriers by enhancing tissue penetration, improving cellular uptake, and facilitating localized drug accumulation, making them particularly advantageous for surgical applications [7].

Advances in Nanotechnology-Based Drug Delivery Systems

Recent advances in nanotechnology have led to the development of a wide range of drug delivery platforms, including liposomes, polymeric nanoparticles, dendrimers, solid lipid nanoparticles, and metallic nanocarriers [8]. These systems are engineered to encapsulate therapeutic agents, protect them from degradation, and deliver them efficiently to target tissues. Their customizable size, surface charge, and functionalization allow for precise modulation of pharmacokinetics and biodistribution, which is critical for optimizing drug therapy in surgical patients [9].

One of the most significant advancements in nanotechnology-based drug delivery is the ability to achieve targeted delivery. Targeting strategies may be passive, such as exploiting the enhanced permeability and retention (EPR) effect in inflamed or tumor tissues, or active, involving the attachment of ligands that bind to specific cellular receptors [10]. These approaches increase drug accumulation at the intended site while reducing exposure to healthy tissues, thereby improving therapeutic outcomes and reducing side effects [11].

Controlled release is another major advancement enabled by nanotechnology. Nanocarriers can be engineered to release drugs in response to specific physiological stimuli, such as changes in pH, temperature, or enzymatic activity commonly present in surgical wounds or tumor microenvironments [12]. This controlled release capability ensures sustained drug availability at the target site, reduces the need for repeated dosing, and enhances patient safety during the postoperative period [13].

Clinical Applications of Nanotechnology in Surgical Drug Delivery

In surgical practice, nanotechnology-based drug delivery systems are increasingly being explored for applications such as targeted chemotherapy, localized antibiotic delivery, enhanced analgesia, and improved wound healing. In oncologic surgery, nanoparticle-mediated chemotherapy allows for higher drug concentrations at tumor margins, reducing recurrence risk while minimizing systemic toxicity. This approach is particularly valuable in patients undergoing tumor resection, where precise postoperative drug delivery is critical [14].

Nanotechnology has also shown promise in preventing and managing surgical site infections. Nanoparticle-loaded antimicrobial agents can be incorporated into surgical dressings, implants, or local delivery systems, providing sustained antimicrobial activity directly at the surgical site. This localized approach reduces the need for prolonged systemic antibiotic use and helps combat antibiotic resistance, a growing concern in surgical care [15].

Furthermore, nanotechnology-based systems are being developed to enhance postoperative pain management and tissue regeneration. Nanoformulated analgesics can provide prolonged pain relief with reduced systemic side effects, while nanomaterials incorporated into scaffolds and wound dressings promote tissue repair, angiogenesis, and controlled drug release. These applications highlight the expanding role of nanotechnology in improving surgical outcomes and patient recovery [16].

Research Objectives

1. To evaluate the effectiveness of nanotechnology-based drug delivery systems in improving targeted drug delivery outcomes among surgical patients.
2. To measure the impact of nanotechnology-enabled controlled drug release on therapeutic efficacy and adverse effect rates in surgical patients.
3. To compare clinical outcomes, including drug bioavailability and postoperative recovery indicators, between nanotechnology-based drug delivery systems and conventional drug delivery methods in surgical care.

Despite advancements in surgical techniques and perioperative care, effective drug delivery in surgical patients remains a significant clinical challenge. Conventional drug delivery methods often result in non-specific drug distribution, rapid systemic clearance, and inadequate drug concentrations at the surgical site, leading to reduced therapeutic efficacy and increased risk of adverse effects. These limitations are particularly critical in surgical patients who require precise, sustained,

and localized drug action for pain management, infection control, and tissue healing. Although nanotechnology-based drug delivery systems have shown promise in improving targeting and controlled release, there is limited quantitative clinical evidence evaluating their effectiveness compared to traditional delivery methods in surgical settings. This gap underscores the need for systematic quantitative research to assess the clinical benefits and limitations of nanotechnology in surgical drug delivery.

This study is significant as it provides quantitative evidence on the clinical effectiveness of nanotechnology-based drug delivery systems in surgical patients. By evaluating targeted delivery efficiency, controlled release outcomes, and postoperative recovery indicators, the findings can contribute to evidence-based improvements in perioperative pharmacological management. The results may support the integration of nanotechnology into surgical drug delivery protocols, leading to enhanced therapeutic efficacy, reduced systemic toxicity, and improved patient outcomes. Additionally, this study can inform clinicians, researchers, and healthcare policymakers about the potential value of nanotechnology in advancing precision medicine and optimizing drug delivery strategies in surgical care.

LITERATURE REVIEW

Overview of Nanotechnology in Drug Delivery

Nanotechnology has emerged as a pivotal advancement in pharmaceutical sciences, particularly in the field of drug delivery, due to its ability to manipulate materials at the molecular and atomic levels. Nanoparticles possess unique physicochemical properties, such as high surface area-to-volume ratios and tunable surface characteristics, which enable enhanced interaction with biological systems. These properties allow drugs to be encapsulated, protected from degradation, and delivered more efficiently to specific tissues or cells. As a result, nanotechnology-based drug delivery systems have gained increasing attention for their potential to improve therapeutic efficacy while reducing systemic toxicity [17].

In clinical medicine, conventional drug delivery methods often fail to achieve optimal drug concentrations at target sites, particularly in complex physiological environments such as those encountered in surgical patients. Factors such as altered blood flow, inflammation, and tissue trauma can significantly affect drug absorption and distribution [18]. Nanotechnology offers solutions to these challenges by enabling controlled drug transport and release, ensuring that therapeutic agents reach the intended site in a predictable and sustained manner. This capability has positioned nanotechnology as a promising approach for enhancing perioperative and postoperative drug management [19].

Despite promising preclinical findings, the translation of nanotechnology-based drug delivery systems into routine clinical practice remains limited. Variability in nanoparticle design, regulatory challenges, and insufficient quantitative clinical data have slowed widespread adoption. Therefore, a thorough examination of existing literature is necessary to evaluate current evidence, identify gaps, and support further quantitative research focused on clinical outcomes in surgical patients [20].

Nanotechnology-Based Drug Delivery Systems

A variety of nanotechnology-based drug delivery platforms have been developed, each with distinct structural and functional characteristics. Common systems include liposomes, polymeric nanoparticles, dendrimers, solid lipid nanoparticles, and inorganic nanocarriers such as gold and silica nanoparticles. These systems are engineered to enhance drug solubility, stability, and bioavailability while allowing precise control over drug release kinetics. Their versatility makes them suitable for delivering a wide range of therapeutic agents, including antibiotics, analgesics, chemotherapeutic agents, and anti-inflammatory drugs used in surgical care [21].

Liposomes are among the most extensively studied nanocarriers due to their biocompatibility and ability to encapsulate both hydrophilic and hydrophobic drugs. Polymeric nanoparticles offer additional advantages, such as controlled degradation and sustained drug release, which are particularly beneficial for prolonged postoperative treatment [22]. Dendrimers, with their highly branched structures, allow for precise drug loading and surface functionalization, enabling advanced targeting strategies. These nanocarriers collectively represent significant advancements in drug delivery technology relevant to surgical applications [23].

Quantitative studies have demonstrated that nanotechnology-based systems improve pharmacokinetic profiles by prolonging drug circulation time and reducing peak plasma concentrations associated with toxicity. However, variability in formulation design and limited standardization across studies complicate direct comparison of outcomes. This highlights the need for robust quantitative evaluations that assess clinical effectiveness using consistent and measurable outcome parameters [24].

Figure 1



Targeted Drug Delivery in Surgical Patients

Targeted drug delivery is a key advantage of nanotechnology-based systems, offering the ability to direct therapeutic agents to specific tissues or cells while minimizing off-target effects. Targeting strategies are broadly classified into passive and active targeting mechanisms. Passive targeting exploits physiological characteristics such as increased vascular permeability in inflamed or tumor tissues, enabling nanoparticles to accumulate preferentially at the target site. This approach has been widely studied in surgical oncology, where enhanced drug concentration at tumor margins is critical

for preventing recurrence [25].

Active targeting involves the functionalization of nanoparticles with ligands, antibodies, or peptides that bind to specific receptors expressed on target cells. This strategy enhances cellular uptake and improves therapeutic specificity. In surgical patients, active targeting has shown potential in delivering chemotherapeutic agents, antimicrobial drugs, and growth factors directly to affected tissues, thereby improving treatment efficacy and reducing systemic adverse effects [26].

Quantitative clinical studies suggest that targeted nanocarriers result in higher local drug concentrations and improved therapeutic indices compared to conventional delivery methods. However, challenges such as receptor heterogeneity, immune recognition, and manufacturing complexity remain barriers to widespread clinical implementation. Further quantitative research is required to determine the consistency and reliability of targeting strategies across diverse surgical populations [27].

Controlled Release Mechanisms and Therapeutic Efficacy

Controlled drug release is another major advantage of nanotechnology-based delivery systems, allowing drugs to be released in a sustained and predictable manner over time. This capability is particularly important in surgical patients, who often require prolonged drug exposure for pain management, infection prevention, and tissue healing. Nanocarriers can be engineered to release drugs gradually or in response to specific stimuli, such as pH changes, temperature variations, or enzymatic activity commonly present in surgical wounds [28].

Stimuli-responsive nanoparticles have demonstrated promising results in maintaining therapeutic drug levels while reducing the need for frequent dosing. Quantitative studies have shown that controlled release systems improve patient compliance, reduce fluctuations in drug concentration, and minimize systemic toxicity. These benefits are especially relevant in postoperative care, where stable drug levels can significantly influence recovery outcomes [29].

Despite these advantages, variability in release kinetics and limited long-term clinical data pose challenges for clinical translation. Differences in surgical wound environments and patient physiology can affect nanoparticle behavior, emphasizing the need for quantitative studies that evaluate controlled release performance under real-world clinical conditions [30].

Figure 2



Clinical Outcomes and Safety Considerations

Clinical outcomes associated with nanotechnology-based drug delivery systems include improved therapeutic efficacy, reduced adverse effects, and enhanced postoperative recovery. Quantitative evidence suggests that nanocarrier-mediated drug delivery can reduce infection rates, improve pain control, and accelerate wound healing in surgical patients. These improvements are attributed to enhanced drug targeting, sustained release, and reduced systemic exposure [31].

Safety remains a critical consideration in the clinical application of nanotechnology. Potential concerns include nanoparticle toxicity, immunogenicity, and long-term accumulation in organs. While many nanocarriers are designed using biocompatible and biodegradable materials, quantitative safety data in surgical populations are still limited. Regulatory agencies require rigorous evaluation of toxicity and pharmacokinetics before clinical approval, underscoring the importance of well-designed quantitative studies [32].

Overall, existing literature supports the potential benefits of nanotechnology-based drug delivery in surgical care but also highlights significant gaps in clinical evidence. Most studies remain preclinical or involve small sample sizes, limiting generalizability. This underscores the need for comprehensive quantitative research to evaluate clinical effectiveness, safety, and cost-effectiveness in surgical patients [33].

METHODOLOGY

This study adopted a quantitative research design to evaluate the clinical effectiveness of nanotechnology-based drug delivery systems in surgical patients, with specific focus on targeted drug delivery efficiency and controlled release outcomes. A prospective comparative study design was employed to allow objective measurement of numerical outcomes related to drug bioavailability, therapeutic efficacy, and adverse effects. The study was conducted in the surgical wards and perioperative units of a tertiary care hospital where nanotechnology-based formulations were administered alongside conventional drug delivery methods as part of routine clinical practice.

The study population consisted of adult surgical patients undergoing elective or emergency surgical procedures who required postoperative pharmacological management. A sample size of 120 patients was included, determined to ensure adequate statistical power for quantitative comparisons. Patients were selected using a consecutive sampling technique and were divided into two groups: those receiving nanotechnology-based drug delivery systems (n = 60) and those receiving conventional drug formulations (n = 60). Inclusion criteria included patients aged 18 years and above who consented to participate, while exclusion criteria included patients with known hypersensitivity to study drugs or severe comorbid conditions affecting drug metabolism.

Data collection focused on quantifiable variables such as drug concentration at target sites, time to achieve therapeutic drug levels, duration of drug action, incidence of adverse effects, and postoperative recovery indicators. Measurements were obtained through laboratory analysis,

clinical assessments, and patient monitoring records. Data analysis was performed using statistical software, with descriptive statistics used to summarize patient characteristics and outcome measures. Inferential statistical tests, including independent samples t tests and chi-square tests, were applied to compare outcomes between groups, with statistical significance set at a p-value of less than 0.05. Ethical approval was obtained from the institutional review board, and all data were handled in accordance with ethical research standards.

RESULTS

Table 1

Effectiveness of Targeted Drug Delivery in Nanotechnology-Based and Conventional Drug Systems (N = 120)

Drug Delivery System	Effective Targeting	Ineffective Targeting	Total
Nanotechnology-Based	48	12	60
Conventional	30	30	60
Total	78	42	120

Note. Chi-square test showed a statistically significant association between drug delivery system type and targeting effectiveness, $\chi^2(1, N = 120) = 10.29, p < .01$.

The results presented in Table 1 indicate that nanotechnology-based drug delivery systems are significantly more effective in achieving targeted drug delivery among surgical patients compared to conventional drug formulations. A substantially higher proportion of patients receiving nanotechnology-based systems achieved effective drug targeting at the surgical site, while conventional delivery methods showed equal proportions of effective and ineffective targeting. The statistically significant chi-square result ($p < .01$) confirms a strong association between the use of nanotechnology-based drug delivery and improved targeting outcomes, supporting the effectiveness of nanotechnology in enhancing precision drug delivery in surgical care.

Table 2

Comparison of Therapeutic Efficacy and Adverse Effects Between Nanotechnology-Based and Conventional Drug Delivery Systems (N = 120)

Drug Delivery System	n	Mean Therapeutic Efficacy Score	Standard Deviation	Adverse Effects n (%)
Nanotechnology-Based	60	82.4	6.8	9 (15.0%)
Conventional	60	71.6	8.5	21 (35.0%)

Note. Independent samples t test showed a statistically significant difference in therapeutic efficacy scores between groups, p < .001.

The findings in Table 2 demonstrate that nanotechnology-enabled controlled drug release systems significantly improve therapeutic efficacy in surgical patients compared to conventional drug delivery methods. Patients receiving nanotechnology-based formulations achieved higher mean therapeutic efficacy scores, indicating more effective and sustained drug action during the postoperative period. Additionally, the lower incidence of adverse effects in the nanotechnology group suggests improved drug tolerability, likely due to controlled and sustained release mechanisms that reduce peak systemic drug concentrations. The statistically significant t-test result ($p < .001$) confirms that controlled release via nanotechnology has a meaningful positive impact on treatment effectiveness and safety in surgical care.

Table 3

Association Between Drug Delivery System and Adverse Effect Occurrence (N = 120)

Drug Delivery System	Adverse Effects Present	No Adverse Effects	Total
Nanotechnology-Based	9	51	60
Conventional	21	39	60
Total	30	90	120

Note. Chi-square test significant at $p < .01$.

To evaluate this objective, a chi-square test of independence was conducted to examine the association between type of drug delivery system and the occurrence of adverse drug effects among surgical patients. Patients were categorized based on whether they experienced adverse effects during the postoperative period. The analysis included a total of 120 patients, equally divided between those receiving nanotechnology-based controlled drug release systems and those receiving conventional drug formulations. The chi-square test revealed a statistically significant association between drug delivery method and adverse effect occurrence, $\chi^2(1, N = 120) = 7.50$, $p < .01$, indicating that the type of drug delivery system significantly influenced adverse effect rates.

The results presented in Table 2 indicate a significant association between nanotechnology-enabled controlled drug release systems and reduced adverse effect rates in surgical patients. A markedly lower proportion of patients receiving nanotechnology-based drug delivery experienced adverse effects compared to those receiving conventional drug formulations. The statistically significant chi-square result ($p < .01$) confirms that controlled release through nanotechnology contributes to improved drug safety, likely by minimizing peak systemic drug concentrations and maintaining stable therapeutic levels. These findings support the clinical advantage of nanotechnology-based controlled drug delivery in enhancing treatment tolerability and patient safety in surgical care.

DISCUSSION

The present quantitative study provides important evidence supporting the clinical value of nanotechnology-based drug delivery systems in surgical patients, particularly in terms of targeted delivery efficiency and controlled drug release. The findings demonstrate that nanotechnology-based systems significantly outperform conventional drug delivery methods in achieving effective drug localization at the surgical site and reducing adverse effects. These results reinforce the growing recognition of nanotechnology as a transformative approach in perioperative pharmacological management, where precision and safety are critical to patient outcomes [34].

With respect to Objective 1, the study found a significantly higher proportion of effective targeted drug delivery among patients receiving nanotechnology-based formulations. This finding is consistent with previous research indicating that nanoparticles enhance drug accumulation at target tissues through mechanisms such as improved permeability, prolonged circulation time, and

surface functionalization for tissue-specific targeting. Earlier studies in surgical oncology and wound management have similarly reported improved drug localization using nanoparticle carriers, supporting the present study's quantitative evidence that nanotechnology enhances precision drug delivery in surgical care [35].

The improved targeting outcomes observed in this study can be attributed to the unique physicochemical properties of nanoparticles, including their small size and modifiable surface characteristics. Prior studies have shown that these properties allow nanoparticles to penetrate inflamed or surgically altered tissues more effectively than conventional formulations. The current findings extend this evidence by quantitatively demonstrating that such targeting advantages translate into clinically meaningful outcomes in surgical patients, rather than remaining limited to experimental or preclinical settings [36].

Regarding Objective 2, the study revealed a significantly lower incidence of adverse drug effects among patients receiving nanotechnology-enabled controlled release systems. This result aligns with earlier research reporting that controlled release formulations reduce peak plasma drug concentrations, thereby minimizing systemic toxicity [37]. Conventional drug delivery methods often expose non-target tissues to high drug levels, increasing the risk of side effects, whereas nanotechnology-based systems maintain more stable and therapeutic drug concentrations over time.

The reduction in adverse effects observed in this study is particularly relevant in surgical populations, who are often vulnerable to drug-related complications due to physiological stress, inflammation, and altered metabolism. Previous clinical and pharmacokinetic studies have emphasized that sustained and controlled drug release improves tolerability and patient safety during the postoperative period [38]. The present findings provide quantitative support for these assertions, highlighting controlled release as a key advantage of nanotechnology in surgical drug delivery.

Furthermore, the findings suggest that nanotechnology-based drug delivery may contribute indirectly to improved postoperative recovery by reducing drug-related complications. Earlier research has shown that adverse effects such as nausea, sedation, and organ toxicity can delay mobilization and wound healing in surgical patients [39]. By minimizing these effects, nanotechnology-based systems may support smoother recovery trajectories, although this warrants further investigation through longitudinal outcome studies.

The results of this study also align with broader trends in precision medicine, where treatment strategies are increasingly tailored to individual patient needs and biological conditions. Previous research has emphasized that nanotechnology enables such personalization by allowing customization of drug release profiles and targeting mechanisms [40]. The quantitative evidence from this study supports the feasibility of integrating nanotechnology-based drug delivery into routine surgical care as part of precision pharmacotherapy.

Despite these positive findings, the results should be interpreted in light of existing challenges highlighted in previous research. Studies have noted that variability in nanoparticle design, cost considerations, and regulatory barriers can limit widespread clinical adoption [41]. While the present study demonstrates clear clinical advantages, future research should focus on cost-effectiveness analyses and standardized formulation protocols to facilitate broader implementation [42].

CONCLUSION

This study concludes that nanotechnology-based drug delivery systems offer significant clinical advantages over conventional drug delivery methods in surgical patients. The findings demonstrate that nanotechnology enhances targeted drug delivery and enables controlled release, resulting in improved therapeutic effectiveness and a reduced incidence of adverse drug effects. By achieving more precise drug localization and maintaining stable therapeutic drug levels, nanotechnology-based systems contribute to safer and more efficient perioperative pharmacological management. These results support the growing role of nanotechnology in advancing precision medicine within surgical care and highlight its potential to improve patient outcomes through optimized drug delivery strategies.

Future Implications

The findings of this study suggest important future implications for clinical practice, research, and healthcare policy. Wider integration of nanotechnology-based drug delivery systems into surgical care could lead to the development of standardized, targeted, and controlled drug delivery protocols that enhance patient safety and therapeutic outcomes. Future research should focus on large-scale, multicenter clinical trials to validate these findings and explore long-term outcomes such as postoperative recovery, hospital length of stay, and cost-effectiveness. Additionally, continued innovation in nanoparticle design and regulatory frameworks will be essential to facilitate safe and widespread clinical adoption, ultimately supporting the evolution of personalized and precision-based surgical pharmacotherapy.

REFERENCES

1. Bhusal, P., et al., Controlled release drug delivery systems to improve post-operative pharmacotherapy. Drug delivery and translational research, 2016. 6(5): p. 441-451. https://doi.org/10.1007/s13346-016-0305-z
2. Simonazzi, A., et al., Nanotechnology applications in drug controlled release, in Drug targeting and stimuli sensitive drug delivery systems. 2018, Elsevier. p. 81-116. https://doi.org/10.1016/b978-0-12-813689-8.00003-3
3. Ciftci, F., et al., Advances in drug targeting, drug delivery, and nanotechnology applications: therapeutic significance in cancer treatment. Pharmaceutics, 2025. 17(1): p. 121. https://doi.org/10.3390/pharmaceutics17010121
4. Güven, E., Nanotechnology-based drug delivery systems in orthopedics. Joint diseases and related surgery, 2021. 32(1): p. 267. https://doi.org/10.5606/ehc.2021.80360

5. Mithany, R.H., et al., Advancements and challenges in the application of artificial intelligence in surgical arena: a literature review. Cureus, 2023. 15(10). https://doi.org/10.7759/cureus.47924
6. Pillai, A., D. Bhande, and V. Pardhi, Controlled drug delivery system, in Advanced drug delivery: Methods and applications. 2023, Springer. p. 267-289. https://doi.org/10.1007/978-981-99-6564-9_11
7. Makvandi, P., et al., Drug delivery (nano) platforms for oral and dental applications: tissue regeneration, infection control, and cancer management. Advanced Science, 2021. 8(8): p. 2004014. https://doi.org/10.1002/advs.202004014
8. Emeihe, E.V., et al., Revolutionizing drug delivery systems: Nanotechnology-based approaches for targeted therapy. Int J Life Sci Res Arch, 2024. 7(1): p. 40-58. https://doi.org/10.53771/ijlsra.2024.7.1.0060
9. Afzal, O., et al., Nanoparticles in drug delivery: from history to therapeutic applications. Nanomaterials, 2022. 12(24): p. 4494. https://doi.org/10.3390/nano12244494
10. Alavi, S.E., et al., Nanoparticle-based drug delivery systems for non-surgical periodontal therapy: innovations and clinical applications. 3 Biotech, 2025. 15(8): p. 269. https://doi.org/10.1007/s13205-025-04443-x
11. Sivakumar, M., Y. Muthu, and K. Elumalai, Advancements in drug delivery systems: a focus on microsphere-based targeted delivery. Biomedical Materials & Devices, 2025. 3(2): p. 1030-1057. https://doi.org/10.1007/s44174-024-00245-6
12. Haleem, A., et al., Applications of nanotechnology in medical field: a brief review. Global Health Journal, 2023. 7(2): p. 70-77. https://doi.org/10.1016/j.glohj.2023.02.008
13. Jilani, M., et al., Recent advances in the clinical application of transferosomes for skin cancer management. Colloids and Surfaces B: Biointerfaces, 2025. 254: p. 114877. https://doi.org/10.1016/j.colsurfb.2025.114877
14. Occhiutto, M.L., et al., Nanotechnology for medical and surgical glaucoma therapy—a review. Advances in therapy, 2020. 37(1): p. 155-199. https://doi.org/10.1007/s12325-019-01163-6
15. Steinberg, D. and M. Friedman, Sustained-release delivery of antimicrobial drugs for the treatment of periodontal diseases: Fantasy or already reality? Periodontology 2000, 2020. 84(1): p. 176-187. https://doi.org/10.1111/prd.12341
16. Khalilov, R., A comprehensive review of advanced nano-biomaterials in regenerative medicine and drug delivery. Advances in Biology & Earth Sciences, 2023. 8(1).
17. Alaswad, M., et al., Point-of-Care Ultrasound in Pediatric Emergency Care in Low-Resource Settings: A Literature Review of Applications, Successes, and Future Directions. Current Treatment Options in Pediatrics, 2025. 11(1): p. 7. https://doi.org/10.1007/s40746-024-00323-3
18. Gaydhane, M.K., C.S. Sharma, and S. Majumdar, Electrospun nanofibres in drug delivery: advances in controlled release strategies. RSC advances, 2023. 13(11): p. 7312-7328. https://doi.org/10.1039/d2ra06023j
19. Kang-Mieler, J.J., C.R. Osswald, and W.F. Mieler, Advances in ocular drug delivery: emphasis on the posterior segment. Expert opinion on drug delivery, 2014. 11(10): p. 1647-1660. https://doi.org/10.1517/17425247.2014.935338
20. Sabzehali, S., Nanomaterials in drug delivery systems: challenges and perspectives. Eurasian Journal of Chemical, Medicinal and Petroleum Research, 2025. 4(1): p. 48-62.
21. Yusuf, A., et al., Nanoparticles as drug delivery systems: a review of the implication of nanoparticles' physicochemical properties on responses in biological systems. Polymers, 2023. 15(7): p. 1596. https://doi.org/10.3390/polym15071596
22. Stanicki, D., et al., An update on the applications and characteristics of magnetic iron oxide nanoparticles for drug delivery. Expert opinion on drug delivery, 2022. 19(3): p. 321-335. https://doi.org/10.1080/17425247.2022.2047020
23. Mehta, S., T. He, and A.G. Bajpayee, Recent advances in targeted drug delivery for treatment of osteoarthritis. Current opinion in rheumatology, 2021. 33(1): p. 94-109. https://doi.org/10.1097/bor.0000000000000761
24. Narayanan, N. and S.M.C. Vigila. A Survey on Enhancing Cloud Data Security Using Blockchain Technology. in 2024 IEEE 16th International Conference on Computational Intelligence and Communication Networks (CICN). 2024. IEEE. https://doi.org/10.1109/cicn63059.2024.10847354
25. Anjum, S., et al., Recent advances in zinc oxide nanoparticles (ZnO NPs) for cancer diagnosis, target drug delivery, and treatment. Cancers, 2021. 13(18): p. 4570. https://doi.org/10.3390/cancers13184570
26. Trucillo, P., Biomaterials for drug delivery and human applications. Materials, 2024. 17(2): p. 456.
27. Shakhakarmi, K., et al., EGF, a veteran of wound healing: highlights on its mode of action, clinical applications with focus on wound treatment, and recent drug delivery strategies. Archives of pharmacal research, 2023. 46(4): p. 299-322. https://doi.org/10.1007/s12272-023-01444-3
28. Chaudhari, R., V. Patel, and A. Kumar, Cutting-edge approaches for targeted drug delivery in breast cancer: beyond conventional therapies. Nanoscale Advances, 2024. 6(9): p. 2270-2286.
29. Acharya, S. and S.K. Sahoo, PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Advanced drug delivery reviews, 2011. 63(3): p. 170-183. https://doi.org/10.1016/j.addr.2010.10.008
30. Abidi, M.H., M.K. Mohammed, and H. Alkhalefah, Predictive maintenance planning for industry 4.0 using machine learning for sustainable manufacturing. Sustainability, 2022. 14(6): p. 3387.
31. Nance, E., et al., Drug delivery to the central nervous system. Nature Reviews Materials, 2022. 7(4): p. 314-331. https://doi.org/10.1038/s41578-021-00394-w
32. Bayer, I.S., Hyaluronic acid and controlled release: A review. Molecules, 2020. 25(11): p. 2649.
33. Sun, T., et al., Engineered nanoparticles for drug delivery in cancer therapy. Nanomaterials and Neoplasms, 2021: p. 31-142. https://doi.org/10.1201/9780429027819-2
34. Rahman, M.A., et al., Fabrication of sustained release curcumin-loaded solid lipid nanoparticles (cur-SLNs) as a potential drug delivery system for the treatment of lung cancer: Optimization of formulation and in vitro biological evaluation. Polymers, 2023. 15(3): p. 542. https://doi.org/10.3390/polym15030542
35. Batool, S., et al., A detailed insight of the tumor targeting using nanocarrier drug delivery system. Drug Delivery, 2023. 30(1): p. 2183815. https://doi.org/10.1080/10717544.2023.2183815
36. Sharifi-Azad, M., et al., Recent advances in targeted drug delivery systems for resistant colorectal cancer. Cancer Cell International, 2022. 22(1): p. 196. https://doi.org/10.1186/s12935-022-02605-y
37. Aquib, M., et al., Advances in local and systemic drug delivery systems for post-surgical cancer treatment. Journal of Materials Chemistry B, 2020. 8(37): p. 8507-8518. https://doi.org/10.1039/d0tb00987c

38. Gaballa, S.A., et al., Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. Drug Delivery and Translational Research, 2021. 11(3): p. 866-893. https://doi.org/10.1007/s13346-020-00843-z
39. Asadipour, E., et al., Nano-biotechnology and challenges of drug delivery system in cancer treatment pathway. Chemistry & Biodiversity, 2023. 20(6): p. e202201072. https://doi.org/10.1002/cbdv.202201072
40. Mansour, A., et al., Drug delivery systems in regenerative medicine: an updated review. Pharmaceutics, 2023. 15(2): p. 695. https://doi.org/10.3390/pharmaceutics15020695
41. Manzari-Tavakoli, A., et al., Integrating natural compounds and nanoparticle-based drug delivery systems: A novel strategy for enhanced efficacy and selectivity in cancer therapy. Cancer medicine, 2024. 13(5): p. e7010. https://doi.org/10.1002/cam4.7010
42. Sharifianjazi, F., et al., Polymer incorporated magnetic nanoparticles: Applications for magnetoresponsive targeted drug delivery. Materials Science and Engineering: B, 2021. 272: p. 115358. https://doi.org/10.1016/j.mseb.2021.115358